Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males

January 2020 | Volume 19 | Issue 1 | Original Article | 78 | Copyright © January 2020


Published online December 13, 2019

Fran E. Cook-Bolden , Michael H. Gold , Eric Guenin

aMount Sinai Health System, New York, NY bTennnessee Clinical Research Center, Nashville, TN cOrtho Dermatologics, Bridgewater, NJ

21. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69:12–19.

22. Dosik JS, Arsonnaud S. Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream 0.05% in subjects with healthy skin. J Drugs Dermatol. 2007;6(6):632-638.

23. Kircik LH. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris. J Drugs Dermatol. 2009;8(7):650-654.

24. Webster GF, Guenther L, Poulin YP, et al. A multi-center, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1 % gel and adapalene 0.1 % gel for the treatment of facial acne vulgaris. Cutis. 2002; 69: 4–11

25. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4:153-158.

26. Tanghetti EA, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):49-558.

27. Kerdel FA, Draelos ZD, Tyring SK, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis. J Dermatolog Treat. 2019;30(4):333-339.

28. Tanghetti AE, Werschler WP, Lain T, et al. Tazarotene 0.045% Lotion for Once- Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from two Phase 3 Trials. J Drugs Dermatol. 2019; in press.

29. Leyden J, Gold LS, Weiss J. Why topical retinoids are the mainstay of therapy for acne. Dermatol Ther. 2017;7(3):293-304.

30. Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.

31. Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne–an evidence- based overview. J Dtsch Dermatol Ges. 2008;6:1023–1031.

32. Thielitz A, Helmdach M, Ropke EM, et al. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145:19–27.

33. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehiclecontrolled study. Cutis. 2006;77:45–50.

34. Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9:549–558.

AUTHOR CORRESPONDENCE

Fran E, Cook-Bolden MD dermdrcookbolden@gmail.com